Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II
Archives of Orthopaedic and Trauma Surgery · 2025
DOI: 10.1007/s00402-025-06057-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Orthopaedic and Trauma Surgery, 2025. Verfasst von Stephanie Kirschbaum und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Musculoskeletal Surgery, Charité - University Medicine Berlin, Berlin, Germany. stephanie.kirschbaum@charite.de. Hauptthemen laut MEDLINE: Iloprost, Knee Joint, Osteonecrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Aims
The aim of this retrospective study was the evaluation of the patient-reported and radiological outcome of intravenous Iloprost therapy in the treatment of spontaneous osteonecrosis of the knee (SONK).
Methods
36 patients (age 57.3 ± 8.7 years, 38.9% women, 61.1% men) who received Iloprost between 2018 and 2021 due to SONK (ARCO I and II) were included in this retrospective cohort study. Outcome was evaluated by pre- and postinterventional pain (Numeric Rating Scale - NRS), patient reported outcome (subjective knee value (SKV), Oxford Knee Score (OKS)) at latest follow-up (2.9 months ± 1) as well as quantitative artificial intelligence assisted analysis of bone marrow edema (BME) in Magnetic Resonance Imaging (MRI) before and after 3 months.
Results
Radiologically, there was a 71% reduction in edema (pre-intervention: 37.0 cm³±37.7, post-intervention: 10.8 cm³ ± 14.9, p < 0.01). Overall satisfaction was 2.0 ± 1.3, SKV was 83.3%±16.6 and NRS at follow-up was 1.3 ± 1.8. OKS reached 33.6 ± 12.0. No major complications were observed. Rare side effects were dizziness which required premature termination of Ilomedin therapy on day 3.
Conclusion
Iloprost treatment seems a safe and promising therapeutic option also in SONK with excellent subjective outcome and reduction of BME of 70% within 3 months after Iloprost infusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Musculoskeletal Surgery, Charité - University Medicine Berlin, Berlin, Germany. stephanie.kirschbaum@charite.de.
- Center for Musculoskeletal Surgery, Charité - University Medicine Berlin, Berlin, Germany.
- Department of Radiology, Charité - University Medicine Berlin, Berlin, Germany.
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Kirschbaum, S., Perka, C., El-Kayali, M., Gwinner, C., Walter-Rittel, T. C., Soujon, M., & Donner, S. (2025). Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II. Archives of Orthopaedic and Trauma Surgery. https://doi.org/10.1007/s00402-025-06057-7
Vancouver
Kirschbaum S, Perka C, El-Kayali M, Gwinner C, Walter-Rittel TC, Soujon M, et al. Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II. Archives of Orthopaedic and Trauma Surgery. 2025. doi:10.1007/s00402-025-06057-7
BibTeX
@article{Kirschbaum2025,
author = {Kirschbaum, Stephanie and Perka, Carsten and El-Kayali, Moses and Gwinner, Clemens and Walter-Rittel, Thula Cannon and Soujon, Maurice and Donner, Stefanie},
title = {Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II},
journal = {Archives of Orthopaedic and Trauma Surgery},
year = {2025},
doi = {10.1007/s00402-025-06057-7}
}
EUVIMED